Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (4313)	7/14/2001 12:45:45 AM
From: Ian@SI	Respond to of 52153

CuraGen Corp (CRGN) 31.20 -0.19: --Before Open-- Southwest Securities initiates coverage with a BUY and a 12-18 month target price of $60; believes that the market for genomic-based drug discovery companies will experience explosive growth driven by the need for pharmaceutical and biotech companies to get drugs to market quicker and cheaper, a market estimated to grow at 40% annually over next 5 years; says CRGN is differentiated from most of its competition by its: 1) scientific credentials, 2) robust proprietary informatics platform, and 3) highly industrialized processes. +++++++= From Briefing.com++++++++++